References
- Cetron, MS, Marfin, AA, Julian, KG, , et al. 2002. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep, 51(RR–17):1–11; quiz CE1–4.
- Fernandes GC, Camacho LA, Sa Carvalho M, Batista M, de Almeida SM. Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999–2005. Vaccine 2007; 25: 3124–3128
- Iskander JK, Miller ER, Chen RT. The role of the Vaccine Adverse Event Reporting system (VAERS) in monitoring vaccine safety. Pediatr Ann 2004; 33: 599–606
- Kitchener S. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX. Vaccine 2004; 22: 2103–2105
- Lindsey NP, Schroeder BA, Miller ER, et al. Adverse event reports following yellow fever vaccination. Vaccine 2008; 26: 6077–6082
- McMahon AW, Eidex RB, Marfin AA, et al. Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases. Vaccine 2007; 25: 1727–1734
- Monath TP. Yellow Fever Vaccine. Vaccines, SA Plotkin, WA Orenstein. Saunders, Philadelphia 2004; 1095–1176
- Sanders EJ, Marfin AA, Tukei PM, et al. First recorded outbreak of yellow fever in Kenya, 1992–1993. I. Epidemiologic investigations. Am J Trop Med Hyg 1998; 59: 644–649
- Varricchio F, Iskander J, Destefano F, et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2004; 23: 287–294